Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.07) by 142.86 percent. This is a 254.55 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $12.053 million which missed the analyst consensus estimate of $12.262 million by 1.71 percent. This is a 8.25 percent increase over sales of $11.134 million the same period last year.
Aquestive Therapeutics Q1 2024 GAAP EPS $(0.17) Misses $(0.07) Estimate, Sales $12.053M Miss $12.262M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.